About Proteasome subunit beta type-5
Proteasome subunit beta type-5 (PSMB5) is a protein
from Homo sapiens identified by UniProt accession
P28074, 263 residues long.
MolForge cross-references it against 0 known binders and
396 disease associations.
Target properties
| Protein name | Proteasome subunit beta type-5 |
|---|
| UniProt accession | P28074 |
|---|
| Gene | PSMB5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 263 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (396)
Diseases linked to this target (Open Targets).
- multiple myeloma · score 0.61
- Mantle cell lymphoma · score 0.53
- neoplasm · score 0.52
- HIV infection · score 0.47
- Waldenstrom macroglobulinemia · score 0.46
- AL amyloidosis · score 0.40
- lymphoid neoplasm · score 0.39
- hypophosphatasia · score 0.37
- thrombotic thrombocytopenic purpura · score 0.37
- Glycogen storage disease due to acid maltase deficiency · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P28074-F1 | alphafold | PREDICTED | 82.37 | — |
Amino-acid sequence (263 residues)
MALASVLERP LPVNQRGFFG LGGRADLLDL GPGSLSDGLS LAAPGWGVPE EPGIEMLHGT TTLAFKFRHG VIVAADSRAT AGAYIASQTV KKVIEINPYL LGTMAGGAAD CSFWERLLAR QCRIYELRNK ERISVAAASK LLANMVYQYK GMGLSMGTMI CGWDKRGPGL YYVDSEGNRI SGATFSVGSG SVYAYGVMDR GYSYDLEVEQ AYDLARRAIY QATYRDAYSG GAVNLYHVRE DGWIRVSSDN VADLHEKYSG STP
Explore Proteasome subunit beta type-5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets